YYÜ GCRIS Basic veritabanının içerik oluşturulması ve kurulumu Research Ecosystems (https://www.researchecosystems.com) tarafından devam etmektedir. Bu süreçte gördüğünüz verilerde eksikler olabilir.
 

The Clinicopathological Features and Survival of Castleman Disease: a Multicenter Turkish Study

dc.authorid Yilmaz, Fatma/0000-0001-6112-3950
dc.authorid Yilmaz, Farise/0000-0001-8136-513X
dc.authorid Eser, Bulent/0000-0002-4513-3486
dc.authorscopusid 57193709115
dc.authorscopusid 57210186649
dc.authorscopusid 57188728728
dc.authorscopusid 57251124400
dc.authorscopusid 59109204200
dc.authorscopusid 57194114271
dc.authorscopusid 6603662687
dc.authorwosid Korkmaz, Serdal/Ist-3736-2023
dc.authorwosid Yılmaz, Fatma/Acx-9470-2022
dc.authorwosid Erkurt, Mehmet/Abi-7232-2020
dc.authorwosid Altuntas, Fevzi/E-8945-2015
dc.authorwosid Bagci, Metin/Aad-2427-2020
dc.authorwosid Ulas, Turgay/A-6050-2018
dc.authorwosid Albayrak, Murat/Juu-5382-2023
dc.contributor.author Yildiz, J.
dc.contributor.author Bagci, M.
dc.contributor.author Sayin, S.
dc.contributor.author Kaya, A.
dc.contributor.author Yilmaz, F.
dc.contributor.author Ekinci, O.
dc.contributor.author Altuntas, F.
dc.date.accessioned 2025-05-10T16:54:05Z
dc.date.available 2025-05-10T16:54:05Z
dc.date.issued 2022
dc.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
dc.department-temp Yildiz J., Department of Hematology, Yenimahalle Training and Research Hospital, Yildirim Beyazit University, Ankara, Turkey; Bagci M., Department of Hematology, Selcuk University, Konya, Turkey; Sayin S., Department of Hematology, Selcuk University, Konya, Turkey; Kaya A., Department of Hematology, Celal Bayar University, Manisa, Turkey; Yilmaz F., Department of Hematology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; Ekinci O., University of Health Sciences, Gazi Yasargil Training and Research Hospital, Department of Hematology, Diyarbakir, Turkey; Dal M.S., Department of Hematology and Apheresis, Unit University of Health Sciences, Ankara Oncology Training and Research Hospital, Ankara, Turkey; Basturk A., Medicana International Istanbul Hospital, Istanbul, Turkey; Aydogdu I., Department of Hematology, Celal Bayar University, Manisa, Turkey; Albayrak M., Department of Hematology, University of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey; Dogan A., Department of Hematology, Yuzuncu Yil University, Van, Turkey; Erkurt M.A., Department of Hematology, Inonu University, Malatya, Turkey; Korkmaz S., Department of Hematology and Apheresis Unit, University of Health Sciences, Kayseri City Training and Research Hospital, Kayseri, Turkey; Ulas T., Department of Internal Medicine, Division of Hematology, Near East University, School of Medicine, Nicosia, Cyprus; Eser B., Department of Hematology, Medical Park Antalya Hospital, Antalya, Turkey; Altuntas F., Department of Internal Medicine, Division of Hematology, Ankara Yildirim Beyazit University, School of Medicine, Ankara, Turkey en_US
dc.description.abstract Objective: In this study, we aimed to investigate the clinicopathological features and survival of CD, which is quite rare and has many unknowns. Patients and Methods: This study was conducted by retrospectively evaluating patients diagnosed with CD in six different centers in Turkey. Results: The median age of 33 patients included in the study was 49 and 51.5% (n = 17) of these patients were women. 18 (54.5%) patients were in the hyaline vascular subtype and most of the patients were UCD (n = 20, 60.6%). The most common involvement region was head and neck (n = 19, 57.5%). The UCD group was younger than the MCD group (p=0.027). Visceral lymph node involvement was higher in MCD than in UCD (p=0.001). Similarly, it was observed that there was more hepatomegaly (p=0.035) and splenomegaly (p=0.013) in the MCD group. During the median 19.5 months follow-up period, there were no patients who died. Conclusions: It was observed that UCD and MCD are different clinical entities. Promising survival times can be achieved with surgical and systemic treatments in both subtypes of this extremely rare disease. However, this result should be supported by well-designed prospective comprehensive studies. © 2022 Verduci Editore s.r.l. All rights reserved. en_US
dc.description.woscitationindex Science Citation Index Expanded
dc.identifier.doi 10.26355/eurrev_202202_28103
dc.identifier.endpage 1137 en_US
dc.identifier.issn 1128-3602
dc.identifier.issue 4 en_US
dc.identifier.pmid 35253168
dc.identifier.pmid 35253168
dc.identifier.scopus 2-s2.0-85125881550
dc.identifier.scopusquality Q2
dc.identifier.startpage 1131 en_US
dc.identifier.uri https://doi.org/10.26355/eurrev_202202_28103
dc.identifier.uri https://hdl.handle.net/20.500.14720/3012
dc.identifier.volume 26 en_US
dc.identifier.wos WOS:000763332500012
dc.identifier.wosquality Q2
dc.language.iso en en_US
dc.publisher Verduci Editore s.r.l en_US
dc.relation.ispartof European Review for Medical and Pharmacological Sciences en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Cd en_US
dc.subject Hyaline Vascular en_US
dc.subject Multicentric Castleman Disease en_US
dc.subject Unicentric Castleman Disease en_US
dc.title The Clinicopathological Features and Survival of Castleman Disease: a Multicenter Turkish Study en_US
dc.type Article en_US

Files